(1 - 12 von 12
)
Genmab CEO worried by takeover risk - paper | Reuters
www.reuters.com
— That worries me sometimes,” Chief Executive Officer Jan van de Winkel told newspaper Het Financieele Dagblad. › article
Tasmanian farmer Jan Winkel - ABC News (Australian Broadcasting...
www.abc.net.au
Tasmanian farmer Jan Winkel. Posted 5 Jun 2019, 9:21pmWed 5 Jun 2019, 9:21pm. Tasmanian farmer Jan Winkel says the towers are "huge". ABC News: ...
Dr Jan van de Winkel joins Hookipa as Chairman of its Board of...
www.manufacturingchemist.com
› ...
Dr. Jan van de Winkel Joins Hookipa as Chairman of its Board of...
sofinnovapartners.com
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and...
Genmab Chief Executive Jan van de Winkel poses for a photograph in...
news.trust.org
Genmab Chief Executive Jan van de Winkel poses for a photograph in London, Britain, October 13, REUTERS/Ben Hirschler
Could J&J's Darzalex success spur it to buy out partner ...
www.chemdiv.com
— And Genmab CEO Jan van de Winkel, for his part, agrees. "Our focus is to build an independent antibody innovation powerhouse,” he told the ... › jjs-dar...
Genmab Announces Appointments of Birgitte Stephensen to
www.globenewswire.com
— Jan van de Winkel, Chief Development Officer Dr. Judith Klimovsky, Chief Financial Officer Anthony Pagano, Chief Medical Officer Dr. Tahi Ahmadi ... › ...
Genmab Appoints Anthony Mancini as COO - New Jersey ...
njbmagazine.com
— Jan van de Winkel, Chief Development Officer Dr. Judith Klimovsky, and Chief Financial Officer Anthony Pagano. Mancini's responsibilities will ... › genmab...
Genmab Licenses DuoBody Platform to Novo Nordisk
www.genengnews.com
— ... collaborations to generate diverse revenue streams in areas beyond cancer,” Genmab CEO Jan van de Winkel, Ph.D., said in a statement. › ge...
Genmab's successful CEO dismisses retirement plans
medwatch.com
— Wednesday, Genmab CEO Jan van de Winkel presented yet another guidance upgrade. Even though he has passed 60 years of age, he underscores — Following an outstandingly profitable year for Genmab, CEO Jan van de Winkel got a pay raise, bringing his annual salary to DKK 37.3m. › News › arti...
Transactions with shares and linked securities in Genmab A/S made by...
view.news.eu.nasdaq.com
— The sale of shares by Jan van de Winkel is partly to honor tax obligations arising out of his participation in Genmab A/S' equity program. › ...
sortiert nach Relevanz / Datum